文献速递糖尿病

2型糖尿病成人一线降糖药使用趋势:SGLT-2i与GLP-1RA新证据下的变化

Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA.
PubMed 文献 · Diabetes Care · 2021-06-18

基于两个美国大型医保数据库,评估2013至2019年2型糖尿病成人初始降糖治疗的趋势与预测因素。二甲双胍仍是最常用一线药物(Medicare 80.6%,商业保险83.1%),SGLT-2i和GLP-1RA使用率低但随时间上升(P<0.01),在有心血管疾病者中更常见。

要点

  • 二甲双胍是绝大多数2型糖尿病患者的首选初始降糖药。
  • 2013至2019年SGLT-2i和GLP-1RA一线使用率低但呈上升趋势。
  • 有心血管疾病者更可能起始SGLT-2i或GLP-1RA。

核心结论

  • 二甲双胍是2型糖尿病成人最常用的一线降糖药。
  • SGLT-2i和GLP-1RA一线使用率低但2013至2019年呈上升趋势。

研究设计与样本

  • 使用两个美国大型医保数据库(Clinformatics和Medicare)识别2013至2019年起始降糖治疗的2型糖尿病成人。
  • 绘制总体及按心血管疾病分层的季度一线治疗使用趋势。
  • 拟合多项逻辑回归估计一线降糖治疗的预测因素,以二甲双胍为参照。

主要发现

  • 二甲双胍使用率:Medicare受益者80.6%,商业保险患者83.1%。
  • 磺脲类使用率:Medicare 8.7%,商业保险4.7%。
  • SGLT-2i使用率:Medicare 0.8%,商业保险1.7%;GLP-1RA使用率:Medicare 1.0%,商业保险3.5%,均呈上升趋势(P<0.01)。
  • 起始SGLT-2i或GLP-1RA者较起始二甲双胍者更年轻,且更常有心血管疾病或更高社会经济地位。

临床怎么用

  • 二甲双胍仍是多数2型糖尿病患者的首选初始降糖药。
  • 对有心血管疾病的患者,可考虑优先起始SGLT-2i或GLP-1RA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated recent use trends and predictors of first-line antidiabetes treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Using two large U.S. health insurance databases (Clinformatics and Medicare), we identified adult patients with type 2 diabetes who initiated antidiabetes treatment from 2013 through 2019. Quarterly trends in use of first-line antidiabetes treatment were plotted overall and stratified by cardiovascular disease (CVD). Multinomial logistic regressions were fit to estimate predictors of first-line antidiabetes treatment, using metformin, the recommended first-line treatment for type 2 diabetes, as the common referent. RESULTS: Metformin was the most frequently initiated medication, used by 80.6% of Medicare beneficiaries and 83.1% of commercially insured patients. Sulfonylureas were used by 8.7% (Medicare) and 4.7% (commercial). Both populations had low use of sodium-glucose cotransporter 2 inhibitors (SGLT-2i, 0.8% [Medicare] and 1.7% [commercial]) and glucagon-like peptide 1 receptor agonists (GLP-1Ra; 1.0% [Medicare] and 3.5% [commercial]), with increasing trends over time (P < 0.01). Initiators of antidiabetes drugs with established cardiovascular benefits (SGLT-2i and GLP-1RA) were more likely to be younger and had prevalent CVD or higher socioeconomic status compared with initiators of metformin. CONCLUSIONS: Among adult patients with type 2 diabetes, metformin was by far the most frequent first-line treatment. While the use of SGLT-2i and GLP-1RA was low from 2013 through 2019, it increased among patients with CVD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Shin H, Schneeweiss S, Glynn RJ, et al. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021. PMID: 34385345. doi:10.2337/dc20-2926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。